Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update

Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 278

Development and validation of an immune gene-set based Prognostic signature in ovarian cancer

Shen, S., Wang, G., Zhang, R., Zhao, Y., Yu, H., Wei, Y., & Chen, F. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.054 · Cited by 254

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Brignone, C., Gutierrez, M., Mefti, F., Brain, E. G. C., Jarcau, R., Cvitkovic, F., Bousetta, N., Médioni, J., Gligorov, J., Grygar, C., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-71 · Cited by 259

Chemoimmunotherapy: Reengineering Tumor Immunity

Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242

Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

Kareva, I., Waxman, D. J., & Klement, G. L. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.039 · Cited by 249

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S. A., Lawrence, D. A., Li, Y., Pitti, R. M., Tótpál, K., Yee, S. F., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 247

Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma

Wu, R. C. H., Forget, M., Chacon, J. A., Bernatchez, C., Haymaker, C., Chen, J. Q., Hwu, P., & Radvanyi, L. G. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d4465 · Cited by 249

Self‐Amplified Drug Delivery with Light‐Inducible Nanocargoes to Enhance Cancer Immunotherapy

Feng, B., Hou, B., Xu, Z., Saeed, M., Yu, H., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201902960 · Cited by 245

Anti-CD20 monoclonal antibodies: historical and future perspectives

Lim, S. H., Beers, S. A., French, R. R., Johnson, P., Glennie, M. J., & Cragg, M. S. (2009) · Haematologica · doi:10.3324/haematol.2008.001628 · Cited by 246

ATP‐Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity

Sun, L., Shen, F., Tian, L., Tao, H., Xiong, Z., Xu, J., & Liu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202007910 · Cited by 243

Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy

Liang, S., Yao, J., Liu, D., Rao, L., Chen, X. S., & Wang, Z. (2023) · Advanced Materials · doi:10.1002/adma.202211130 · Cited by 245

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects

Jia, H., Truica, C. I., Wang, B., Wang, Y., Ren, X., Harvey, H. A., Song, J. J., & Yang, J. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.002 · Cited by 246

Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

Liu, S., Foulkes, W. D., Leung, S., Gao, D., Lau, S., Kos, Z., & Nielsen, T. O. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0432-8 · Cited by 236

NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target

Chen, W. (2010) · Frontiers in bioscience · doi:10.2741/3782 · Cited by 234

More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer

Haen, S. P., Pereira, P. L., Salih, H. R., Rammensee, H., & Gouttefangeas, C. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/160250 · Cited by 233

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Gujar, S. A., Pol, J. G., Kim, Y., Lee, P. W. K., & Kroemer, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 234

Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis

Khosravi, N., Stoner, L. R., Farajivafa, V., & Hanson, E. D. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.08.187 · Cited by 240

Radiation-induced effects and the immune system in cancer

Kaur, P., & Asea, A. A. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00191 · Cited by 233

Relevance of tumor-infiltrating lymphocytes in breast cancer

Dushyanthen, S., Beavis, P. A., Savas, P. S., Teo, Z. L., Zhou, C., Mansour, M., Darcy, P. K., & Loi, S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0431-3 · Cited by 228

Carrier-free nanodrugs for safe and effective cancer treatment

Karaosmanoglu, S., Zhou, M., Shi, B., Zhang, X., Williams, G. R., & Chen, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.014 · Cited by 225

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 222

Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies

Apétoh, L., Tesnière, A., Ghiringhelli, F., Kroemer, G., & Zitvogel, L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0427 · Cited by 224

Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer

Mikhail, A. S., Morhard, R., Mauda‐Havakuk, M., Kassin, M. T., Arrichiello, A., & Wood, B. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115083 · Cited by 223

Heterogeneity and treatment landscape of ovarian carcinoma

Veneziani, A. C., González-Ochoa, E., Alqaisi, H. A., Madariaga, A., Bhat, G. R., Rouzbahman, M., Sneha, S., & Oza, A. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00819-1 · Cited by 228

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Joseph, E. L. M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 212

Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy

Huang, J., Xiao, Z., An, Y., Han, S., Wu, W., Wang, Y., Guo, Y., & Shuai, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120636 · Cited by 210

Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update

Engle, K., & Kumar, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114542 · Cited by 219

Ipilimumab-associated Hepatitis

Johncilla, M. E., Misdraji, J., Pratt, D. S., Agoston, A. T., Lauwers, G. Y., Srivastava, A., & Doyle, L. A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000453 · Cited by 208

Advances in drug delivery for post-surgical cancer treatment

Bu, L., Yan, J., Wang, Z., Ruan, H., Chen, Q., Gunadhi, V., Bell, R. B., & Gu, Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.027 · Cited by 211

TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells

Fang, H., Ang, B., Xu, X., Huang, X., Wu, Y., Sun, Y., Wang, W., Li, N., Cao, X., & Wan, T. Y. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.59 · Cited by 214

Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling

Ko, A., Kanehisa, A., Martins, I., Senovilla, L., Chargari, C., Dugué, D., Mariño, G., Kepp, O., Michaud, M., Perfettini, J., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.124 · Cited by 212

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

Thomas, R., Al‐Khadairi, G., & Decock, J. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600573 · Cited by 209

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202

Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β

Kim, J., Phan, T. X., Nguyen, V. H., Dinh-Vu, H.-V., Zheng, J. H., Yun, M., Park, S., Hong, Y., Choy, H. E., Szardenings, M., et al. (2015) · Theranostics · doi:10.7150/thno.11432 · Cited by 204

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

Leonetti, A., Wever, B. M. M., Mazzaschi, G., Assaraf, Y. G., Rolfo, C. D., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 202

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action

Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R., & Lesterhuis, W. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960317 · Cited by 219

Angiotensin II Drives the Production of Tumor-Promoting Macrophages

Cortez‐Retamozo, V., Etzrodt, M., Newton, A., Ryan, R. J. H., Pucci, F., Sio, S. W. S., Kuswanto, W. F., Rauch, P. J., Chudnovskiy, A., Iwamoto, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.015 · Cited by 201

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Wouters, M. C. A., Kenter, G. G., van Erkel, A. R., van Poelgeest, M. I. E., Nijman, H. W., van der Hoeven, J. J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv309 · Cited by 201

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Wang, Y., Zhang, W., Han, Q., Liu, Y., Dai, H., Guo, Y., Bo, J., Fan, H., Zhang, Y., Zhang, Y.-J., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.10.002 · Cited by 197

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

Kamath, S. D., Kalyan, A., Kircher, S. M., Nimeiri, H. S., Fought, A. J., Benson, A. B., & Mulcahy, M. F. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 200

Chemotherapy and radiotherapy: Cryptic anticancer vaccines

Ma, Y., Kepp, O., Ghiringhelli, F., Apétoh, L., Aymeric, L., Locher, C., Tesnière, A., Martins, I., Ly, A., Haynes, N. M., et al. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.001 · Cited by 198

Exploration of Zinc Oxide Nanoparticles as a Multitarget and Multifunctional Anticancer Nanomedicine

Wang, J., Lee, J. S., Kim, D., & Zhu, L. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11219 · Cited by 192

Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation

Lian, Q., Xu, J., Yan, S., Huang, M., Ding, H., Sun, X., Bi, A., Ding, J., Sun, B., & Geng, M. (2017) · Cell Research · doi:10.1038/cr.2017.54 · Cited by 191

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

Sheng, J., Fang, W., Yu, J., Chen, N., Zhan, J., Ma, Y., Yang, Y., Huang, Y., Zhao, H., & Zhang, L. (2016) · Scientific Reports · doi:10.1038/srep20090 · Cited by 190

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Nishio, M., Mok, T. S. K., Reck, M., Finley, G. G., Kaul, M. D., Yu, W., Paranthaman, N., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7711 · Cited by 191

Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Liu, D., Chen, B., Mo, Y., Wang, Z., Qi, T., Zhang, Q., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02306 · Cited by 186

Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy

Fumagalli, G., Monza, L., Cavaletti, G., Rigolio, R., & Meregalli, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.626687 · Cited by 183

Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer

Huang, Y., Guan, Z., Dai, X., Shen, Y., Qin, W., Ren, L., Jiang, J., Xiao, Z., Jiang, Y., Liu, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24564-0 · Cited by 184

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells

Duewell, P., Steger, A., Lohr, H., Bourhis, H., Hoelz, H., Kirchleitner, S. V., Stieg, M. R., Grassmann, S. A., Kobold, S., Siveke, J. T., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.96 · Cited by 180

Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy

Lees, J. G., Makker, P. G. S., Tonkin, R. S., Abdulla, M., Park, S. B., Goldstein, D., & Moalem‐Taylor, G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.006 · Cited by 180

Enhancing in situ cancer vaccines using delivery technologies

Gong, N., Alameh, M., El-Mayta, R. D., Xue, L., Weissman, D., & Mitchell, M. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00974-9 · Cited by 197

Cancer immunotherapy

Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902937809 · Cited by 183

Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer

Shevchenko, I., Karakhanova, S., Soltek, S., Link, J., Bayry, J., Werner, J., Umansky, V., & Bazhin, A. V. (2013) · International Journal of Cancer · doi:10.1002/ijc.27990 · Cited by 168

Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?

Bruttel, V. S., & Wischhusen, J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00360 · Cited by 177

Biodegradable star HPMA polymer–drug conjugates: Biodegradability, distribution and anti-tumor efficacy

Etrych, T., Kovář, L., Strohalm, J., Chytil, P., Řı́hová, B., & Ulbrich, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.015 · Cited by 173

Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine

He, S., Cheng, P., & Pu, K. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01009-1 · Cited by 177

High hydrostatic pressure induces immunogenic cell death in human tumor cells

Fucikova, J. P., Moserova, I. K., Truxová, I., Heřmanová, I., Vančurová, I., Partlová, S., Fialová, A., Sojka, L., Cartron, P., Houška, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28766 · Cited by 180

CX3CR1 identifies PD-1 therapy–responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Yan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A. A., Jang, J. S., Jen, J., Li, Y., Chanana, P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97828 · Cited by 170

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

Menard, C., Martin, F., Apétoh, L., Bouyer, F., & Ghiringhelli, F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0505-6 · Cited by 175

Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes

Bellone, M., & Calcinotto, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00231 · Cited by 167

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027469 · Cited by 168

Use of tumour-responsive T cells as cancer treatment

Disis, M. L., Bernhard, H., & Jaffee, E. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60404-9 · Cited by 167

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

Wagner, A. H., Devarakonda, S. H. K., Skidmore, Z. L., Krysiak, K., Ramu, A., Trani, L., Kunisaki, J., Masood, A., Waqar, S. N., Spies, N. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06162-9 · Cited by 160

Targeting macrophages rescues age‐related immune deficiencies in C57 BL/6J geriatric mice

Jackaman, C., Radley‐Crabb, H. G., Soffe, Z., Shavlakadze, T., Grounds, M. D., & Nelson, D. J. (2013) · Aging Cell · doi:10.1111/acel.12062 · Cited by 162

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 166

Bone metastasis and the metastatic niche

Ren, G., Esposito, M., & Kang, Y. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1329-4 · Cited by 167

Immunotherapy of hepatocellular carcinoma

Pardee, A. D., & Butterfield, L. H. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18344 · Cited by 162

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma

Autio, M. I., Leivonen, S., Brück, O. E., Mustjoki, S. M., Jørgensen, J. M., Karjalainen‐Lindsberg, M., Beiske, K., Holte, H., Pellinen, T. S., & Leppä, S. (2020) · Haematologica · doi:10.3324/haematol.2019.243626 · Cited by 163

Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression

Berghuis, D., Santos, S. J., Baelde, H. J., Taminiau, A. H. M., Egeler, R. M., Schilham, M. W., Hogendoorn, P. C. W., & Lankester, A. C. (2010) · The Journal of Pathology · doi:10.1002/path.2819 · Cited by 159

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

Brunsvig, P. F., Kyte, J. A., Kersten, C., Sundstrøm, S. H., Møller, M., Nyakas, M., Hansen, G. L., Gaudernack, G., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1385 · Cited by 159

Nanobiomaterial-based vaccination immunotherapy of cancer

Chen, F., Wang, Y., Gao, J., Saeed, M., Li, T., Wang, W., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120709 · Cited by 159

Classification of Chemotherapeutic Agents Based on Their Differential In vitro Effects on Dendritic Cells

Tanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1101 · Cited by 162

Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy

Saeed, M., Gao, J. X., Shi, Y., Lammers, T., & Yu, H. (2019) · Theranostics · doi:10.7150/thno.37568 · Cited by 155

Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment

Roblyer, D. M., Ueda, S., Cerussi, A. E., Tanamai, W., Durkin, A. F., Mehta, R. S., Hsiang, D. J. B., Butler, J., McLaren, C. E., Chen, W., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013103108 · Cited by 151

Targeting immune checkpoints in breast cancer: an update of early results

Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157

Trial watch: Peptide-based vaccines in anticancer therapy

Bezu, L., Kepp, O., Cerrato, G., Pol, J. G., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 158

The Microenvironment of Lung Cancer and Therapeutic Implications

Mittal, V., Rayes, T. E., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos‐Hoff, M. H. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_5 · Cited by 154

Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors

Lin, A. G., Xiang, B., Merlino, D. J., Baybutt, T. R., Sahu, J., Fridman, A., Snook, A. E., & Miller, V. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484978 · Cited by 156

Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets

Kumar, A. R., Devan, A. R., Nair, B., Balachandran, V., & Nath, L. R. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06752-9 · Cited by 162

Multi‐shelled Dendritic Mesoporous Organosilica Hollow Spheres: Roles of Composition and Architecture in Cancer Immunotherapy

Yang, Y., Lu, Y., Abbaraju, P. L., Zhang, J., Zhang, M., Xiang, G., & Yu, C. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701550 · Cited by 153

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy

de Charette, M., & Houot, R. (2018) · Haematologica · doi:10.3324/haematol.2017.184192 · Cited by 129

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma

Wong, E. T., Lok, E., Gautam, S., & Swanson, K. D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.238 · Cited by 155

A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting

He, Y., Lei, L., Cao, J., Yang, X., Cai, S., Tong, F., Huang, D., Mei, H., Luo, K., Gao, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.aba0776 · Cited by 148

Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis

van der Velden, W. J. F. M., Herbers, A. H. E., Netea, M. G., & Blijlevens, N. M. A. (2014) · British Journal of Haematology · doi:10.1111/bjh.13113 · Cited by 146

Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone

Zhou, S., Shang, Q., Wang, N., Li, Q., Song, A., & Luan, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.035 · Cited by 148

A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors

Chhabra, N., & Kennedy, J. M. (2021) · Journal of Medical Toxicology · doi:10.1007/s13181-021-00833-8 · Cited by 155

iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery

Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139

Polysaccharide-based nanomedicines for cancer immunotherapy: A review

Zeng, Y., Xiang, Y., Sheng, R., Tomás, H., Rodrigues, J., Gu, Z., Zhang, H., Gong, Q., & Luo, K. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.008 · Cited by 150

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142

Anticancer metal drugs and immunogenic cell death

Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 147

Dysfunction of antigen processing and presentation by dendritic cells in cancer

Bandola-Simon, J. M., & Roche, P. A. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.03.025 · Cited by 142

DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins

de Andrade, L. F., Smyth, M. J., & Martinet, L. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.95 · Cited by 151

Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities

Ganapathy‐Kanniappan, S. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.04.002 · Cited by 144

Dendritic Cells and Cancer: From Biology to Therapeutic Intervention

Wylie, B., Macri, C., Mintern, J. D., & Waithman, J. C. (2019) · Cancers · doi:10.3390/cancers11040521 · Cited by 149

Role of the microbiota in response to and recovery from cancer therapy

Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 151

Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set

Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 141

Current Advances in Black Phosphorus‐Based Drug Delivery Systems for Cancer Therapy

Liu, W., Dong, A., Wang, B., & Zhang, H. (2021) · Advanced Science · doi:10.1002/advs.202003033 · Cited by 139

B cell-regulated immune responses in tumor models and cancer patients

Fremd, C., Schütz, F., Sohn, C., Beckhove, P., & Domschke, C. (2013) · OncoImmunology · doi:10.4161/onci.25443 · Cited by 138

Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death

Zappasodi, R., Pupa, S. M., Ghedini, G. C., Bongarzone, I., Magni, M., Cabras, A. D., Colombo, M. P., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1825 · Cited by 149

Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma

Ganesan, A.-P., Johansson, M., Ruffell, B., Beltran, A., Lau, J., Jablons, D. M., & Coussens, L. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301317 · Cited by 140

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328